Citadel Advisors
GYRE icon

Citadel Advisors’s Gyre Therapeutics GYRE Stock Holding History

Citadel Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-53
Closed -$211 – 15023
2022
Q4 		$211 Buy
+53
New +$216 ﹤0.01% 14727
2022
Q3 		– Sell
-1,400
Closed -$19K – 13009
2022
Q2 		$19K Buy
+1,400
New +$9.3K ﹤0.01% 12423
2021
Q2 		– Sell
-1,987
Closed -$75K – 13970
2021
Q1 		$75K Buy
1,987
+374
+23% +$17.1K ﹤0.01% 12686
2020
Q4 		$76K Buy
+1,613
New +$69.8K ﹤0.01% 10367
2020
Q3 		– Sell
-2,013
Closed -$89K – 10317
2020
Q2 		$89K Sell
2,013
-14
-0.7% -$657 ﹤0.01% 9057
2020
Q1 		$66K Buy
+2,027
New +$93.2K ﹤0.01% 8893
2018
Q4 		– Sell
-2,600
Closed -$210K – 9375
2018
Q3 		$210K Sell
2,600
-253
-9% -$20K ﹤0.01% 8145
2018
Q2 		$250K Buy
+2,853
New +$500K ﹤0.01% 7524
2014
Q4 		– Sell
-1
Closed -$2K – 8577
2014
Q3 		$2K Sell
1
-6
-86% -$14.8K ﹤0.01% 7998
2014
Q2 		$26K Buy
+7
New +$22.8K ﹤0.01% 7160
2014
Q1 		– Sell
-3
Closed -$8K – 7906
2013
Q4 		$8K Sell
3
-7
-70% -$27.6K ﹤0.01% 6752
2013
Q3 		$44K Sell
10
-8
-44% -$32.2K ﹤0.01% 5862
2013
Q2 		$60K Buy
+18
New +$68.5K ﹤0.01% 5563

Other funds holding GYRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors's GYRE Position: Q4 2023 in Review

Citadel Advisors sold out of Gyre Therapeutics (GYRE) in Q4 2023, closing a stake of 3,198 shares — an estimated $23.1K sold.

Citadel Advisors first reported a position in GYRE in Q2 2013 and held it in 27 quarters. The position peaked at $2.71M in Q1 2020. 16 funds tracked by Wall St. Rank hold GYRE as of Q4 2023.

  • Citadel Advisors reported no remaining Gyre Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Citadel Advisors sold 3,198 Gyre Therapeutics shares in Q4 2023, an estimated $23.1K.
  • Citadel Advisors first reported a position in Gyre Therapeutics in Q2 2013 and held it in 27 quarters.
  • Citadel Advisors's Gyre Therapeutics position peaked at $2.71M in Q1 2020.
  • 16 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2023.

Based on Citadel Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.